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Abstract
Medicine is constantly looking for new and improved treatments for diseases, which need to have a high efficacy and
be cost-effective, creating a large demand on scientific research to discover such new treatments. One important
aspect of any treatment is the ability to be able to target only the illness and not cause harm to another healthy part
of the body. For this reason, metallic nanoparticles have been and are currently being extensively researched for their
possible medical uses, including medical imaging, antibacterial and antiviral applications. Superparamagnetic metal
nanoparticles possess properties that allow them to be directed around the body with a magnetic field or directed to
a magnetic implant, which opens up the potential to conjugate various bio-cargos to the nanoparticles that could
then be directed for treatment in the body. Here we report on some of the current bio-medical applications of various
metal nanoparticles, including single metal nanoparticles, functionalized metal nanoparticles, and core-shell metal
nanoparticles using a core of Fe3O4 as well as synthesis methods of these core-shell nanoparticles.
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Introduction
Metal nanomaterials represent a significant doorway for
the future of medicine. Although there is still much un-
known about the long-term safety of metal nanoparticles
in medicine [1], these particles have already found their
place within various biomedical applications such as site-
specific imaging in vivo [2–4], cancer detection [5, 6], can-
cer therapy [7–10], neurodegenerative disease therapy
[11–13], HIV/AIDS therapy [14–16], ocular disease ther-
apy [17–19], and respiratory disease therapy [20, 21]. Fig-
ure 1 presents a range of current uses for nanoparticles in
medicine. Despite the recent advances in nanomedicine,
there are still many obstacles in the way of nano-therapy,
such as it can be hard to achieve a synthesis route which
produces easily repeatable results, with many nanoparticle
synthesis methods producing a range in both size [22–24]
and shape [25–28] of nanoparticles and/or do not produce
the nanomaterials in a large enough quantity to make it
economically viable [29]. Another key factor is that it is
relatively unknown as to the long-term toxicity of some
nanoparticles over a period of time due to how relatively
new the field of research is [30–32]. Among the many
possible uses of metal nanoparticles lies the area of drug
delivery [33, 34]. Due to the large surface area that nano-
particles provide [35], they possess the ability to be able to
deliver large quantities of drugs or other medical cargoes
[36]. An alternative to single metal nanoparticles is to in-
corporate a core to the nanoparticle which has alternative
properties to the shell material, and one example of this is
to incorporate a magnetic core. One challenge that still
presents itself is synthesizing core-shell nanoparticles;
there are many ways to synthesize nanoparticles [37], but
new challenges emerge when attempting to synthesize a
core-shell nanoparticle [38].
This review first focuses on some of the methods cur-
rently used to generate core-shell nanoparticles focusing
on using cores of Fe3O4 and coatings of gold or silver.
We then examine current bio-medical applications of
single metal nanoparticles, their limitations, and how to
overcome them with the application of magnetic cores.
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Synthesis of Core-Shell Nanoparticles
Methods for the synthesis of metallic nanoparticles have
been known for many years, for example, Stevenson et al.
published a synthesis for gold nanoparticles via the reduc-
tion of HAuCl4 in 1951 [39]. Since then, there have been
many different routes for nanoparticle synthesis such as
gas deposition [40], sol-gel [41], and aerosol/vapor phase
[42]. However, a new challenge presents itself when
attempting to synthesize metal nanoparticles consisting of
a core-shell structure, in which one metal forms the core
and a second metal forms the shell, for example Fe parti-
cles degrade in water, whilst HAuCl4 is a strong oxidizing
agent [38]. One such example that will be discussed fur-
ther is using a Fe3O4 (iron oxide) core and gold as the
coating shell. In the preparation of such core-shell metal
nanoparticles, two of the biggest issues are attempting to
control the rate of coating and controlling the uniformity
of the coating to create a solution of nanoparticles which
are all of very similar shape and size [43]. Coating of gold
or silver onto an iron oxide core can be divided into two
main categories: direct coating of gold/silver onto iron
[44] or using an intermediary layer to act as a glue be-
tween the gold and the iron layer [45]. The former cat-
egory will be discussed here. The following text describes
some methods that have been devised to synthesize gold-
and silver-coated Fe3O4 nanoparticles.
Reverse Micelle Synthesis
A popular route for synthesizing metal nanoparticles is
to use the reverse micelle method, or sometimes called
the microemulsion route [46]. This method was first in-
troduced in the 1980s when colloidal solutions of rho-
dium, platinum, and palladium nanoparticles were first
synthesized [47].
Micelles are formed when molecules with hydrophobic
and hydrophilic constituent parts come into contact with
either an aqueous or hydrophobic phase [48]. The mi-
celles will organize themselves in such a way that allows
the hydrophilic part to be in contact with the aqueous
phase and the hydrophobic constituent facing the hydro-
phobic phase [49]. In essence, a spheroid is formed with
an inner shielded phase, which can furthermore contain
a cargo [43, 50–52].
There are different approaches to the microemulsion
route and these include water-in-oil (w/o) [53] and
water-in-supercritical CO2 (w/sc-CO2) [54]. A w/o emul-
sion occurs when water is dispersed in a hydrocarbon-
based continuous phase [53], thermodynamically driven
surfactant self-assembly, and then generates the reverse
micelles, with spherical micelles being the most common
shape [43]. Any added polar or ionic materials added to
this mixture become compartmentalized within the mi-
celles, and nanoparticles are then formed when the mi-
celle membranes come into contract with each other
through Brownian motion [55]. A w/sc-CO2 emulsion in-
volves using a fluid (CO2) that is in a supercritical state,
i.e., above both its critical pressure and temperature [56].
This method holds particular interest as it is a more
“green” approach to nanoparticle synthesis as no toxic or-
ganic solvents are required. It is also easier to recoup the
Fig. 1 Some of the current uses of nanoparticles in medicine
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product by simply lowering the pressure and releasing the
fluid as CO2 gas [57].
The reverse micelle route has been adapted from synthe-
sizing metal nanoparticles to coating previously synthesized
nanoparticles [58]. The first gold-coated iron oxide (Au-
Fe3O4) nanoparticles synthesized in reverse micelles were
done so almost 20 years ago [59]. This synthesis of Au-
Fe3O4 nanoparticles was done using a H2O/CTAB (cetyltri-
methyl ammoniumbromide) system to produce the mi-
celles with sodium borohydride (NaBH4) as the reducing
agent, reducing gold chloride (HAuCl4) onto the iron core.
This synthesis produced a nanoparticle dispersion with an
average size of 12 nm. Since this is the first production of
Au-Fe3O4 NPs using microemulsions, there has been a
range of Au-Fe3O4 NPs synthesis routes discovered [46,
60–63]. Figure 2 is a generic representation of how the
nanoparticles are formed using the reverse micelle route.
Lin et al. published a slightly modified method to coat
Fe3O4 with gold using a reverse micelle method [60]. The
synthesis also employs a system using CTAB as the surfac-
tant to form the reverse micelle, but with 1-butanol as a
co-surfactant and octane as the oil phase, adding a water
solution containing the metal ions using NaBH4 to reduce
HAuCl4 onto the surface of the iron oxide nanoparticles.
The reported optical results of the coated particles showed
a shift in the absorbance peak of the UV/vis spectra from
the gold colloid (526 nm) to the Au-Fe3O4 (555 nm). The
TEM results of the coated particles indicated a size distri-
bution of 5–15 nm, with an average size of 10 nm. This
method was repeated by Pana et al. with a slightly larger
size distribution of 5–35-nm-sized Au-Fe3O4 nanoparti-
cles [63]. In addition, a very similar system has been
employed by Seip et al. with the exception of using hydra-
zine to reduce the HAuCl4 [64].
The coating of Fe3O4 nanoparticles is not limited to just
gold; Lopez Perez et al. reported on the synthesis of iron
oxide nanoparticles using a system containing cyclohexane/
Brij-97 (co-surfactant) and an aqueous phase with iron salts
of FeSO4.7H2O and FeCl3.6H2O [65]. This system has been
coated with both silver [58] and gold [46], producing 13-
nm particles. An alternative method is reported by Tamer
et al. for the synthesis of Au-Fe3O4 nanoparticles [62]. This
method employs a co-precipitation of iron salts in
NaOH, which were then washed in HClO4 to produce
oxidized Fe3O4 nanoparticles. Coating of gold onto
the Fe3O4 NPs occurred via the reduction of HAuCl4
by NaOH delivered to the system by CTAB micelles.
Au-Fe3O4 NPs were produced with an average size of
23.5 nm. After characterization, particles were then
modified with various functional groups to form a
self-assembled monolayer (SAM) and further used for
the capturing and detection of Escherichia coli.
A modified version of the reverse micelle synthesis has
been done by Zhang et al. involving the use of a laser as
the initiator for the coating of iron nanoparticles with gold
[66]. The process involves making a reaction mixture of
iron nanoparticles encapsulated in CTAB micelles, gold
nanopowder in water, and octane, then irradiating with a
pulsed laser while vigorously stirring the reaction. The
laser irradiation facilitates the thermal decomposition of
the gold nanoparticles. Gold atoms and clusters formed
around the iron nanoparticles, forming gold-coated iron
nanoparticles. The TEM results for the Au-Fe nanoparti-
cles synthesized this way gave an average size of 18 nm
with a size distribution of ±36 nm.
Thermal Synthesis
Among the various methods of gold shell-iron core nano-
particle synthesis lies a thermal route, wherein the reac-
tion involves heating the reaction mixture to above its
boiling point [67], and sometimes refluxing [68, 69]. There
are two main categories for this type of synthesis: hydro-
thermal (water-based solvent) [70, 71] and solvothermal
(organic-based solvent) [68, 72]. While there are many
techniques for synthesizing metal nanoparticles via the
thermal route [73–78], it is not possible to achieve the
synthesis of the cores and coating of gold in a one pot re-
action [68, 69, 72, 74, 77, 79–81], and in some cases,
Fe3O4 cores are synthesized via a reverse micelle route
[70] or a colloidal route [78] and then the particles are
coated using a hydro- or solvothermal technique [70, 76,
78]. While there are a variety of solvent systems that are
Fig. 2 A generic representation of the interaction of reverse micelles containing salts the react to form metal nanoparticles
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used in these synthetic methods, the majority of routes in-
volve the addition of either iron oxide nanoparticles to
boiling HAuCl4 or the inverse of HAuCl4 being added to
boiling solutions of iron oxide nanoparticles [74, 79].
A method for the synthesis of Au-Fe3O4 nanoparticles
has been done by Rudakovskaya et al. via a hydrothermal
technique [76]. The principle of the method follows the
addition of Fe3O4 nanoparticles to a boiling HAuCl4 so-
lution. TEM analysis of these nanoparticles indicated an
average size of 30 nm, with a general spherical shape and
a size distribution between 20 and 35 nm; these images
can be seen in Fig. 3.
Colloidal Synthesis
Colloidal synthesis techniques offer a simple yet effective
way of synthesizing metal nanoparticles [82]. Colloidal
techniques often offer a level of simplicity over other
techniques for nanoparticle synthesis, without the need
for different solvents, or that it can be carried out at
room temperature [83, 84]. The basic principles of the
synthesis involve dispersing different metal ions in an
aqueous phase, adding a reducing agent to the mixture,
then mixing at a controlled temperature to form insol-
uble nanoparticles [39]. Colloidal synthesis routes offer
the benefit of not having to involve potential toxic sol-
vents in the synthesis (ideal if the nanoparticles are
intended for biological use). However, there are some
limitations to colloidal routes such as it can be hard to
control the size distribution of the final synthesized
nanoparticles [85] and the shape of the nanoparticles
can be heavily influenced by reagent concentration [85].
On the positive side, it can however be easier to produce
nanoparticles in a larger quantity [86]. This method for
metal nanoparticle synthesis has been around for many
years, being used for the synthesis of different types of
nanoparticles such as silver [87] and gold [39, 88].
This basic method has been advanced and developed to
produce different synthetic routes for the formation of
gold-coated iron oxide nanoparticles [83, 84, 89–97]. Most
of the methods for the synthesis of gold-coated iron oxide
revolve around using various reducing agents to reduce
HAuCl4 onto the surface of the iron oxide. Nadagouda et
al. offer a proposed “green” synthetic route, using ascorbic
acid to reduce HAuCl4 [84]. This method however seems
to show little to no control over size or shape of the
coated nanoparticles due to the lack of capping agent (an
agent that binds to the outside of the nanoparticle that
stops further “growth” of the nanoparticle) used in the
synthesis [98]. A method which does show more control
over the shape and size of synthesized coated particles is
presented by Pal et al. [95] This method employs gold
acetate as the gold salt, which is reduced onto the surface
of 6-nm Fe3O4 nanoparticles to create 7-nm-sized Au–
Fe3O4 particles, which are spherical in shape. A rapid
method for coating Fe3O4 nanoparticles is presented by
Rawal et al. which involves dispersing Fe3O4 nanoparticles
in a solution of HAuCl4, then mixing with ethanol [83].
After 15min at room temperature, the reaction was
stopped and the Au-Fe3O4 nanoparticles were then sepa-
rated with a magnet. TEM analysis of the purified solution
showed that the particles produced ranged in size from 30
to 100 nm and had varied shapes across the sample; these
images can be seen in Fig. 4. While this synthesis tech-
nique produced the coated nanoparticles quickly, it does
not appear to be a very efficient synthesis for production
of uniformly shaped and sized particles [83].
While some techniques offer just the reduction of gold
salts, others prefer to put the reducing agent onto the
surface of the iron, such as hydroxylamine [90, 93]. In
many cases when Fe3O4 nanoparticles are coated with
gold, the reduction of a gold salt yields standard gold
nanoparticles as well [74], so the addition of the
Fig. 3 A TEM image of the nanoparticles synthesized by
Rudakovskaya et al. As can be seen, the nanoparticles are roughly
spherically shaped with an average size of 30 nm [76]
Fig. 4 A TEM image of the nanoparticles synthesized by Rawal et al.
These nanoparticles have a size distribution of 20–100 nm [83]
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reducing agent onto the surface of the iron nanoparticles
aims to improve the efficiency of the coating and is
intended to lower the quantity of gold nanoparticles pro-
duced as a by-product [93].
Another technique involves seeding gold onto the surface
of magnetic nanoparticles which provides a more direct
route of getting gold to nucleate around the magnetic core
of the nanoparticles [91, 92, 97]. This technique involves
binding gold seeds, which are smaller than the iron oxide
nanoparticles in solution, to the surface of the iron oxide.
When the HAuCl4 is reduced in solution, the Au
+ ions will
seed onto the iron oxide and form a shell around the iron
oxide nanoparticles. This gold seeding has been successfully
employed by several groups; Goon et al. used polyethylenei-
mine to control the seeding of gold onto the surface of
Fe3O4, producing fully coated nanoparticles. [91] However,
the synthesized Au-Fe3O4 particles displayed high polydis-
persity, with particle size ranging from 40 to 110 nm. Levin
et al. managed to produce gold shell-magnetic core nano-
particles with a size range of 50–70 nm, using a core func-
tionalized with organosilane molecules to bind to the gold
seeds [92]. Seeding of gold nanoparticles onto an iron core
can be demonstrated with a variety of core shapes, for ex-
ample, Wang et al. demonstrated gold seeding onto rice-
shaped “Nano rice” Fe3O4 structures, which then led to a
complete thick gold shell when gold was reduced onto the
surface [97].
Bio-Medical Applications of Metal Nanoparticles
Antimicrobial Agents
Bacterial infections are very common, with antibiotics
being a primary method of treatment since the discov-
ery of penicillin in 1928 by Alexander Fleming [99].
Nanomedicine provides us with a new, broad range of
possible treatment modalities, with metal nanoparticles
being explored for future treatments [100]. Table 1 lists
some of the nanoparticles that have been explored for
antimicrobial applications. One material that has been
examined for its potential use is silver, which has shown
to have a variety of biomedical uses [101], for example,
Sreekumar et al. utilized silver nanoparticles as part of
a network of antimicrobial fibers. The nanoparticles
varied in size from 20 to 120 nm, with an antibacterial
efficacy against Escherichia coli as high as 94.3% com-
pared to the fibers without silver nanoparticles [102].
While it has been shown that an antibiotic such as
ampicillin is capable at achieving a kill rate of ≤ 99.9%
in E. coli [103], the same study also reported the emer-
gence of resistance to ampicillin in certain strains of E.
coli. On this same note, it has been reported that E. coli
can develop a resistance to silver nanoparticles; how-
ever, this resistance is not a genetic change, but it is a
physical response that attempts to cause the colloidal
nanoparticles to aggregate [104]. Also employing silver
for its antibacterial properties, Holtz et al. designed a
system of 60-nm silver vanadate nanowires ‘decorated’
with silver nanoparticles with a diameter of 1–20 nm
[105]. This system showed to be promising against three
Staphylococcus aureus strains and also interestingly had a
much lower growth inhibiting concentration against
methicillin-resistant Staphylococcus aureus (MRSA) than
the antibiotic oxacillin.
A silver nanoparticle synthesis was reported by Verma
et al. where they employed their nanoparticles against the
bacteria: Pseudomonas fluorescens, E. coli, and the fungus
Candida albicans [106]. The silver nanoparticles had an
average minimum inhibitory growth concentration of
5.83 μg/ml across the three strains, compared to some
commonly used antibiotics such as ampicillin and neomy-
cin which have minimum inhibitory growth concentra-
tions of 4.0 μg/ml and 16.0 μg/ml, respectively, against
strains of E. coli [110]. Of potential interest is the proper-
ties the nanoparticles displayed against P. fluorescens an C.
albicans, both of which are associated with causing dis-
ease in immunocompromised patients [111]. Further in-
vestigations might find that the silver nanoparticles are a
more efficient way to treat the pathogens than some of
Table 1 List of antibacterial properties that have been exhibited by some metal nanoparticles and metal nanoparticle conjugates
Type of nanoparticle Size
(nm)
Antimicrobial application Mechanism of action Ref




E. coli Bacterial growth inhibition [102]
Silver vanadate
nanowires
1–20 S. aureus Bacterial growth inhibition [105]
Naked silver 10–25 C. albicans, P. fluorescens, E. coli Bacterial growth inhibition [106]
Thioguanine-capped
gold
3–4 E. coli, A. fumigatus, P. aeruginosa, and anticancer
effect against Hep2
Bacterial growth inhibition, cellular toxicity [107]
Naked gold 25 C. pseudotuberculosis Vacuole formation in cell wall and agglomeration of
NPs within cells
[108]
Naked gold 6–40 S. aureus, K. pneumonia, B. subtilis Bacterial growth inhibition [109]
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the most commonly used antibiotics, such as amphoteri-
cin B, which has extensive side effects [112].
The synthesis of thioguanine-capped gold nanoparticles
has been reported by Selvaraj et al. where an enhanced
antimicrobial effect against several bacterium, including:
E. coli, Aspergillus fumigatus, and Pseudomonas aerugi-
nosa [107]. It was found that the thioguanine-capped gold
nanoparticles were more effective than unconjugated thio-
guanine as anticancer and antimicrobial agents, with their
activities showing potential use as carriers for cancer
drugs. In a similar manner, gold nanoparticles have been
reported to have an antimicrobial effect on Corynebacter-
ium pseudotuberculosis [108], nanoparticles with an aver-
age size of 25 nm, using a dose of 50 μg/ml showed a
bacterial growth inhibition of 95% after 20min of expos-
ure. Similarly, naked gold nanoparticles were shown to
have an antimicrobial effect on a variety of gram negative
and gram positive bacteria including S. aureus, Klebsiella
pneumonia, and Bacillus subtilis [109]. A dose of 1.35 μg/
ml of AuNPs showed a growth inhibition of 46.4±0.4%,
38.3±0.2%, and 57.8±0.2% for S. aureus, K. pneumonia,
and B. subtilis, respectively.
Antiviral
As with antibacterial applications, metal nanoparticles
have shown to be promising in antiviral applications;
Table 2 demonstrates a range of nanoparticles that have
been shown to possess antiviral properties and could po-
tentially be applied when treating viruses. Both naked
and coated silver nanoparticles [113–116] have been
shown to have a range of antiviral applications when in
the nano-scale range.
Hepatitis B (HBV) is a viral infection that currently af-
fects 257 million people around the world and was re-
sponsible for 887,000 deaths in 2015 according to the
World Health Organization [121]. Small (10–50 nm)
naked silver nanoparticles have been tested as a possible
treatment for HBV [113] and were shown to bind effi-
ciently to HBV and further inhibit the production of
HBV RNA. The mode of action is hypothesized to be
due to the AgNPs binding to the HBV dsDNA (double-
stranded DNA). Rogers et al. have demonstrated a use
for silver nanoparticles, both naked and with a polysac-
charide coating as an antiviral agent against monkeypox
virus (MPV) [114]. The nanoparticles were tested in
vitro against MPV at a range of concentrations between
12.5–100 μg/ml; the results of the study showed that all
of the concentrations of polysaccharide-coated silver
nanoparticles (Ag-PS-NPs) used were able to reduce
MPV-induced plaque formations in vitro.
Silver nanoparticles may even have a role to play in
the treatment of human immunodeficiency virus (HIV)
[115, 116]. HIV is a major health concern, with WHO
estimating that 36.7 million people are living with HIV
as of 2016 [122]. It is important that treatments for HIV
are discovered and implemented quickly and efficiently;
Lara et al. have demonstrated the effect of silver nano-
particles (30–50 nm) on HIV-1 isolates showing inhib-
ition of all strains of HIV-1 isolates [116]. The naked
nanoparticles showed an overall IC50 of 0.44 mg/ml ± 0.3
against HIV-1, with the mechanism of viral inhibition
shown to be the inhibition of virus-host cell binding,
specifically the silver nanoparticles inhibit the inter-
action between the gp120 protein (an envelope glycopro-
tein) and the target cell membrane receptors. Also
demonstrated by the same group was the ability for sil-
ver nanoparticles coated with polyvinylpyrrolidone
(PVP) to prevent the transfection of HIV-1 into a human
cervical tissue explant model [115]. Specifically, 0.15 mg/
ml PVP-coated silver nanoparticles (PVP-AgNPs) inhib-
ited infection by HIV-IIIB and HIV-AZT-RV isolates. This
concentration of PVP-AgNPs also induced a prolifera-
tion of lymphocytes (immune cells) to the site of infec-
tion, in comparison to the control sample [115].
Table 2 Some of the metal nanoparticles and metal nanoparticle conjugates that have been demonstrated as having antiviral
properties
Type of nanoparticle Size
(nm)
Antiviral application Mechanism of action Ref
AgNPs 10–50 Hepatitis B virus (HBV) Interaction with DNA and/or binding with
virus particles
[113]
Ag-PS-NPs 10–80 Monkeypox virus (MPV) Blocking of virus-host cell binding and penetration [114]
PVP-AgNPs 30–50 Human immunodeficiency virus
type 1 (HIV-1)
Prevention of HIV-1 transfection [115,
116]
Au-MES 4 Herpes simplex virus type 1 (HSV-1) Competition with host cell binding [117]
Gold coated with an amphiphilic
sulfate ligand
2 Human immunodeficiency virus type
1 (HIV-1)
Binding to gp120 [118]
Copper iodide (CuI) nanoparticles 100–
400
Feline calicivirus (FCV) ROS generation and subsequent capsid
protein oxidation
[119]
Copper iodide (CuI) nanoparticles 160 Influenza A of swine origin (H1N1) Generation of hydroxyl radicals and degradation of
viral proteins
[120]
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It is not only silver and coated silver nanoparticles that
have been employed against viruses: 2-nm gold nanoparti-
cles coated with an amphiphilic sulfate ligand were also
shown to be effective against HIV-1 [118]. These particles
were shown to target the fusion process of the virus and
were shown in vitro to bind to gp120 protein and directly
neutralize the HIV-1 infection. Mercaptoethanesulfonate-
coated gold nanoparticles (Au-MES) showed an inhibition
of herpes simplex virus type 1 (HSV-1) infection, possibly
by inhibiting the virus binding to the host cell, cell to cell
viral spreading, or alteration of cell susceptibility to viral in-
fection induced by the presence of the nanoparticles [117].
Copper-iodide nanoparticles (CuI-NPs) have been
shown to have antiviral properties on several different vi-
ruses: feline calicivirus (FCV) [119] and more interestingly
influenza A virus of swine origin (H1N1) [120]. One hun-
dred to 400 nm CuI-NPs showed an antiviral property
when utilized against FCV, and it was hypothesized that
monovalent Cu ions were responsible for the production
of a reactive oxygen species (ROS) that caused subsequent
capsid protein oxidation, leading to FCV inactivation.
H1N1 virus was also shown to be inhibited by CuI-NPs,
in a very similar manner, namely the production of hy-
droxyl radicals, leading to protein degradation. However,
these radicals might also prove to be toxic to non-infected
tissues, which would be important to determine before a
treatment would be approved for use [123].
Imaging
Magnetic resonance imaging (MRI) scanning is a very use-
ful tool for medical diagnosis and provides clear anatomical
images. Using MRI, one can visualize the blood flow,
physiochemical traits, and the states of tissues and organs
in the body [124]. Contrast agents are often employed in
MRI for improved diagnostic sensitivity [125]. Convention-
ally used contrast agents are chelate-based, but the major
drawbacks of current contrast agents are their biological
stability and their toxicity levels when accumulated in cells
[126]. For example, some contrast agents are iodine-based,
and it has been reported that iodinated contrast media ex-
posure is associated with subsequent development of inci-
dent hyperthyroidism and incident overt hypothyroidism
[127]. Alternatives have been developed to provide an im-
proved scanning efficacy by reducing the negative impact
contrast agents can have on the body [128]. Alternatives in-
clude metal nanoparticles possibly conjugated with an
agent which acts in a similar manner to a contrast agent for
MRI scanning [129]. Figure 5 is an MRI contrast image of a
rat cerebral cortex pre- and post-treatment of AuNPs [130].
Table 3 shows some of the nanoparticles that have been
explored for use in medical imaging. Some computed
tomography (CT) contrast agents have issues including
short circulation half-lives [131] and potential tissue dam-
age [130]. Due to this, metal nanoparticles have also been
investigated for use in CT imaging [132]; Au nanoparticles
show promising use in imaging due to their X-ray attenu-
ation [133]. Kojima et al. showed that gold nanoparticles
conjugated with a PEGylated dendrimer (PEG-AuNPs)
made for a superior contrast agent in vitro as well as for
X-ray computed tomography, compared to the commer-
cially available iodine agent iopamidal [134]. The PEG-
AuNPs showed a higher contrast efficiency than the com-
mercially available iopamidal, with rapid excretion from
the body [135]. The authors also noted that the PEG-
AuNPs had photocytotoxic properties to enable photo-
thermal therapy.
Li et al. have demonstrated the use of coated AuNPs
as an imaging tool for atherosclerosis; the AuNPs were
applied in a type of medical imaging called “single-pho-
ton emission computed tomography” (SPECT) [136].
This type of imaging is very similar to using a gamma
camera, but it is able to provide true 3D images that
can be sliced, rotated, and manipulated to achieve a
more accurate analytical technique [136]. The modified
nanoparticles specifically targeted atherosclerosis pla-
ques containing apoptotic macrophages, indicating a
useful tool for invasively accurate detection of athero-
sclerosis plaques [136].
AuNPs have previously been demonstrated to be a pos-
sible agent for photoacoustic imaging (PA), showing high
spatial resolution and sensitivity [137]. PA relies on the de-
tection of ultrasonic waves which are emitted from tissues
when exposed to non-ionizing pulsed laser irradiation
[140]. The intensity/magnitude of the ultrasonic emission
is responsible for the image contrast, therefore any agent
that can both absorb the laser pulses and then give off
heat as a result will increase the magnitude of the ultra-
sonic emission and AuNPs possess the ability to do both
of these [141, 142]. AuNPs are potentially better than or-
ganic dyes due to the organic dyes’ susceptibility to photo-
bleaching and rapid clearing from the blood [143]. AuNPs
Fig. 5 An MRI contrast image of a rat cerebral cortex pre- (left)
and post-treatment (right). The area containing the AuNPs is
ringed in red
Anderson et al. Nanoscale Research Letters          (2019) 14:188 Page 7 of 16
also have use in cell imaging for examining movement of
nanoparticles within cells when conjugated with various
cargoes. Figure 6 is a darkfield imaging of A431 lung
cancer cells treated with AuNPs that target epidermal
growth factor receptor, and the bright areas within the
cells are the nanoparticles indicating their locations
within the cells [144].
Biomedical Cargo Delivery
Nanoparticles make for an ideal molecule for drug deliv-
ery due to the huge surface area to the volume ratio they
provide when compared to their bulk material [145]. In
addition, it is possible to engineer nanoparticles to either
avoid or interact with the immune system in specific ways
[146, 147]. For example, it has been demonstrated that an
increased hydrophobicity of nanoparticles/sub-groups
conjugated to the nanoparticles illicit and increased im-
mune response by measuring cytokine mRNA levels in
mice [146]. Focusing in the opposite direction, it has been
suggested that nanoparticles can be conjugated with vari-
ous ligands to directly activate the immune system to
target the destruction of a tumor [148] or by accumulation
in the liver or spleen for the generation of tolerance or im-
munity, respectively [147].
Gold nanoparticles have been extensively studied for
their delivery of medical cargo, for example, Bhumkar et
al. have explored the application of AuNPs for trans-
mucosal delivery of insulin. Gold nanoparticles were
synthesized in the presence of chitosan, which acts as a
polymeric stabilizer [149]. These nanoparticles were then
loaded with insulin and administered both nasally and
orally to diabetic rats. The results showed an overall re-
duction in the rat’s blood glucose levels, an indication of
successful movement of the nanoparticles through the
mucosal membranes and into the bloodstream.
More recently “smart” AuNPs have been employed in
PA [138]. These nanoparticles are roughly 10 nm in diam-
eter and are functionalized with citraconic amide moieties
which are susceptible to hydrolysis. The citraconic amides
are converted into positively charged primary amino acids
at a mildly acidic pH, while the surface molecules adopt
negative charges at physiological pH [138]. Combined,
these two properties cause the “smart” nanoparticles to
adopt both positive and negative charges allowing them to
aggregate rapidly due to electrostatic attraction. These
nanoparticles are referred to as “smart” due to the nano-
particles presenting cancer-specific properties and accu-
mulate rapidly and efficiently in cancer tissues and show a
much lower accumulation in normal tissues [150].
Gold nanoparticles can also be used as a delivery sys-
tem for nucleic acids [153], including oligonucleotides
[151] and small interfering RNA (siRNA) [154]. Many
different methods have been developed to functionalize
AuNPs with nucleic acids, for example, Yonezawa et al.
have synthesized gold nanoparticles modified with thio-
choline, which then bound to DNA and formed a fusion
of wire-like structures throughout the DNA [155]. Sand-
ström et al. demonstrated the ability to bind nucleic
acids onto gold nanoparticles [151], and a similar modi-
fication has been done by Rosi et al. where tetrathiol-
modified antisense oligonucleotides were bound to 13-
nm gold nanoparticles [152]. Being able to conjugate nu-
cleic acids to nanoparticles opens up the possibility of
targeted gene delivery, which could, for example, lead to
genes coding for a specific protein to be delivered to a
Table 3 Some examples of metal nanoparticles and metal nanoparticle-conjugates that have been investigated for their use in
medical imaging
Type of nanoparticle Size (nm) Scanning type Ref
PEG-AuNPs 3–8 CT [135]
Modified AuNPs 17–23 SPECT/CT [136]
AuNPs 130–147 PA [137]
AuNPs with citraconic amide moieties 10 PA [138]
AuNPs in combination with radiotherapy 25 Dual-energy CT [139]
Fig. 6 Darkfield imaging of A431 lung cancer cells treated with
AuNPs; the bright yellow/orange dots are nanoparticles within
the cells
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cell that was either deficient in that protein or could not
produce the protein themselves [156]. It has also been
exhibited that gold nanoparticles modified with DNA
can transfect cancer cells [157] (Table 4).
Anticancer Drug Delivery
Cancer is one of the world’s leading killers with large
areas of scientific research being dedicated to the fight
against cancer, and nanoparticles offer a new doorway
into methods to target and treat cancer. Table 5 pre-
sents a selection of nanoparticle/drug conjugates that
have been tested for anticancer treatments. Paciotti et
al. have investigated the application of PEGylated
AuNPs as a carrier for tumor necrosis factor (TNF)
which is a cell-signaling protein that possess the ability
to induce apoptosis in healthy cells [158]. The Au-
PEG-TNF nanoparticles were injected intravenously
and agglomerated significantly more in MC-38 colon
carcinoma cells compared to other healthy cells/tissues.
The TNF not only gave therapeutic action on the MC-
38 cells, but also seemed to possess a targeting prop-
erty, indicated by the lack of agglomeration in healthy
cells. Another interesting observation reported was the
ability for the Au-PEG-TNF nanoparticles to diminish a
tumor mass compared to “free” TNF.
Doxorubicin is a widely used cancer therapeutic agent
but has dose-limiting associations with cardiotoxicity.
A gold nanoparticle-doxorubicin conjugate has been
developed that demonstrates little no to cardiotoxicity
to mice while being able to treat cancer [160]. Dixit et
al. demonstrated the selective delivery of folic acid-
coated AuNPs into folate receptor (FR) positive cancer
cells, whereas when compared with a cell line that did
not have folate receptors, uptake was shown to be min-
imal [159]. These results demonstrated the use of folate
to target metal nanoparticles to FR-positive cancer cells
for tumor imaging and ablation.
Limitations of Single Metal Nanoparticles and
Overcoming Them
The principal obstacle with nanoparticle drug delivery
is the ability to direct the nanoparticle to the target
area [162, 163]. There are several methods in use for
metal nanoparticle targeting such as antibodies [164–
166] and homing peptides [167, 168]. There are how-
ever limitations to these methods, with the biggest be-
ing that before they even reach the desired target cells
they have to pass through a variety of other barriers,
such as blood vessels and the blood-brain barrier [169].
One way to overcome this targeting limitation is to use
magnetic nanoparticles [170]. A magnetic nanoparticle-
targeting system works by directing the nanoparticles
to a target site using an external magnetic field, it has
already been demonstrated that the magnetic anisot-
ropy of the nanoparticle is a very important factor for
medical treatments [171], with a change in anisotropy
being able to the change the efficacy of hypothermia
treatments for example [172]. Superparamagnetic metal
nanoparticles have this property (they only present
magnetic properties while in the presence of a magnetic
field) [173]. However, the benefit of magnetic nanopar-
ticles also presents a potential limitation, due to the
toxicity of many magnetic materials [31, 174, 175]. Des-
pite iron being approved for various imaging uses [5, 6,
31], it has been suggested in several studies that naked
iron oxide nanoparticles may have some adverse effects
when used in cell labeling [176–178]. One method that
can be used to overcome any potential toxicity limita-
tions is to coat the iron core [179]. A range of materials
can be used as the coating material: silica [180–182],
polymers [183, 184], gold [62, 93, 95, 185], or silver [58,
186]. Gold has low pharmaceutical activity [187] and
silver has been used in biomedical applications for
many years [188, 189],
The combination of a superparamagnetic core with an
inert and safe metal coating produces metal nanoparti-
cles with superior characteristics to non-magnetic metal
particles [190]. As well as reducing toxicity, the coating
also provides the potential for the conjugation of func-
tionalized molecules onto the surface, such as drugs and
biomolecules for application in the medical field [97,
140, 152]. It is of note that a core-shell nanoparticle still
possesses the properties and uses of a nanoparticle made
from the same material as just the shell, but the super-
paramagnetic core gives the ability to direct the nano-
particle in the body [191]. For example, a gold
nanoparticle with an antibody is classified as a targeting
Table 4 A range of nanoparticle conjugates that have been examined for medical delivery of cargos
Type of Nanoparticle Size
(nm)
Medical delivery application Ref
Chitosan stabilized AuNPs 10–50 Delivery of insulin across transmucosal membranes [149]
AuNPs conjugated to an oligonucleotide modified with thiol groups 10–20 Delivery of nucleic acids as a potential for gene
therapy
[151]
AuNPs conjugated to antisense oligonucleotide modified with tetra-thiol
groups
13 Delivery of nucleic acids as a potential for gene
therapy
[152]
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nanoparticle, introducing the core would classify the
nanoparticle as a directed targeting nanoparticle [173].
Current Medicinal Uses of Gold-Coated Iron Oxide
Nanoparticles
Core-shell superparamagnetic nanoparticles have already
been assessed for their biomedical uses, with a wide range
of uses already being applied [192] and with a majority of
research investigating into the use of gold as a shell for
the nanoparticles, in part due to its biocompatibility and
ability to easily bind to a variety of materials. As such, this
section will deal exclusively with gold shell nanoparticles.
One of these uses is as a magnetic carrier for drug target-
ing [192–196]. Kayal and Ramanujan have tested an in
vitro apparatus that simulates the human circulatory sys-
tem as a test for the magnetic delivery of gold-coated iron
oxide nanoparticles (Au-Fe3O4) loaded with doxorubicin
[194]. Their system had various magnetic fields of increas-
ing strength next to a capillary through which the
doxorubicin-loaded particles were passed. A significant
percentage of these nanoparticles were captured within
the magnetic fields, strongly indicating the potential for
the use of magnetic nanoparticles in drug delivery. An-
other use for a targeted system is the application of Au-
Fe3O4 nanoparticles in photothermal therapy. Bhana et al.
demonstrated the use of a core-shell system used in com-
bination therapy deployed against two different cancer cell
lines; head and neck (KB-3-1) and breast (SK-BR-3) with a
reported decrease in cell viability of 64% when they ex-
posed cell lines to a combined photothermal and photo-
dynamic therapy, compared to each modality used on its
own [197]. In photothermal therapy, gold nanoparticles
are coated with a ligand, such as PEG [142], and these
nanoparticles are irradiated with a laser, with a wavelength
that matches the UV-vis λ-max of the gold nanoparticles
[194]. The nanoparticles vibrate at the laser’s frequency
which causes heat to be released causing the death of the
surrounding tissue [198], introducing a core which is
superparamagnetic can allow for a more accurate target-
ing for use in this therapy. Similarly, it has been reported
by Kirui et al. that gold hybrid nanoparticles were de-
ployed against SW1222 colorectal cancer in photothermal
therapy, showing an increased case of cellular apoptosis
after therapy, with their conclusion being that the cells
showed an increased uptake, leading to a reduced laser
power required to reach threshold therapeutic levels
[199]. The use of core-shell nanoparticles for photother-
mal therapy of cancer has also been reported by other
groups [200, 201].
Metal nanoparticles have already shown to have a
place in contrast imaging, for example core-shell nano-
particles can also be used in T1- and T2-weighted im-
aging in MRI [202]. Research by Cho et al. demonstrated
that gold-coated iron nanoparticles can be successfully
used in MRI imaging, as well as opening the route for
conjugating various ligands for use in biosensors [202].
A magnetic carrier capable of imaging and photothermal
therapy has been reported by Cheng et al. They demon-
strated the magnetic targeting of multi-functional nano-
particles to a tumor in a mouse model, which could be
imaged inside the tumor and showed a reduction in the
tumor size when combined with photothermal therapy
[203]. It is also of note that in this work, both the nano-
particle dosage (1.6 mg/kg) and laser power (1W/cm2)
are among the lowest applied for in vivo photothermal
therapy. Moreover, there was no obvious toxicity from
the nanoparticles reported. Table 6 presents some of the
currently reported uses of core-shell nanoparticles.
Another medical area where such core-shell metal
nanoparticles have been suggested to make an impact is
in directed enzyme prodrug therapy (DEPT) [170, 191].
DEPT is a promising method of cancer treatment, with
several therapies making it through to clinical trials
[207, 208]. The main principal of DEPT is the targeted
delivery of a prodrug-activating enzyme to a tumor site.
Upon arrival at the tumor site, the enzyme enters the
target cells where it can later activate an administered
prodrug. However, the efficacy of the therapy depends
on the ability to direct the enzyme to the tumor site,
with current directional techniques relying on passive
targeting methods such as viruses [207, 209] or anti-
bodies [210, 211], rather than an active targeting system
for enzyme delivery. A novel therapy proposed by Gwe-
nin et al. potentially overcomes the targeting issue [170,
212]. This approach involves conjugating a genetically
modified prodrug-activating enzyme onto the surface of
Table 5 A range of nanoparticle conjugates that have been examined for anticancer therapy
Type of nanoparticle Size
(nm)
Medical delivery application Ref
PEGylated AuNPs conjugated with
TNF
30–34 Delivery of TNF to cancer cells targeted by the TNF itself, TNF induces cell apoptosis [158]
AuNPs conjugated with folic acid
using a PEG linker
10 Delivery of folic acid (vitamin B9), a precursor for nucleic acid production [159]
AuNPs loaded with doxorubicin 30–40 Delivery of doxorubicin-loaded gold nanoparticles for tumor targeting/therapy [160]
AuNPs coated with a tumor specific
uptake peptide
25–40 Drug delivery to lymphoma cells with gold nanoparticles conjugated with cellular uptake
peptides specific to lymphoma cells
[161]
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a gold-coated iron oxide superparamagnetic nanoparticle
(AuMNP), then directing the AuMNP-enzyme conjugate
to the target site using a magnetic field to increase the
efficacy of the targeted therapy. Figure 7 presents some
of the uses of a core-shell nanoparticle.
Conclusions
In brief, single metal nanoparticles have been shown to cur-
rently possess a wide range of biomedical applications, with
more application for these nanoparticles being discovered.
One of the limiting factors that these nanoparticles face in
medical treatments is to find a way for precise accurate tar-
geting of areas within the body, be it for targeting of a drug
delivery or for therapies involving the nanoparticles directly.
A way to overcome this is to employ a magnetic core to
create core-shell nanoparticles that can then be directed
around a body using a magnetic field. There are a variety of
methods that can be used to synthesize these core-shell
nanoparticles, with each method having its own advantages
and disadvantages. There remain many obstacles for core-
shell nanoparticles before they can be routinely applied in
the medical field and these include
1) Achieving a synthesis route which produces easily
repeatable results;
2) Producing particles of a set size [22–24] and shape
[25–28]; and
3) Producing large enough quantities to make it
economically viable [29].
Table 6 Examples of the medical uses already been demonstrated for gold-coated iron magnetic nanoparticles
Type of nanoparticle Medical application Ref
Gold-coated iron oxide Targeted delivery of doxorubicin [194]
Gold-coated iron oxide Photothermal and photodynamic combination anticancer treatment [197]
Gold hybrid nanoparticles Photothermal anticancer therapy [199]
Gold-coated iron nanoparticles T1- and T2-MRI imaging [202]
Multifunctional gold nanoparticle Magnetically directed tumor targeting in mice for phototherapy and imaging of the particles [203]
Multifunctional gold-coated iron oxide Cancer diagnosis and therapy [204]
Gold-coated iron oxide Cancer therapy [205]
Gold-coated iron oxide MRI/PA imaging [206]
Fig. 7 A pictorial representation of the applications of core/shell nanoparticles
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Another key factor is the relatively unknown toxicity
of some nanoparticles over an extended period of time
due to how relatively new the field of research is.
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